Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

CEO

ISIN

US0453962070

WKN

000A402CB

Listings

0 Comments

Share your thoughts

FAQ

What is Assembly Biosciences stock price today?▼

The current price of V7B.F is €23.8 EUR — it has decreased by -4.42% in the past 24 hours. Watch Assembly Biosciences stock price performance more closely on the chart.

What is Assembly Biosciences stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Assembly Biosciences stocks are traded under the ticker V7B.F.

Is Assembly Biosciences stock price growing?▼

V7B.F stock has fallen by -4.42% compared to the previous week, the month change is a +3.48% rise, over the last year Assembly Biosciences has showed a +191.67% increase.

What is Assembly Biosciences market cap?▼

Today Assembly Biosciences has the market capitalization of 376.44M

When is the next Assembly Biosciences earnings date?▼

Assembly Biosciences is going to release the next earnings report on May 07, 2026.

What were Assembly Biosciences earnings last quarter?▼

V7B.F earnings for the last quarter are 1.2 EUR per share, whereas the estimation was -0.74 EUR resulting in a +262.69% surprise. The estimated earnings for the next quarter are N/A EUR per share.

What is Assembly Biosciences revenue for the last year?▼

Assembly Biosciences revenue for the last year amounts to 54.13M EUR.

What is Assembly Biosciences net income for the last year?▼

V7B.F net income for the last year is -76.25M EUR.

When did Assembly Biosciences complete a stock split?▼

The last stock split for Assembly Biosciences was on February 12, 2024 with a ratio of 1:12.